SKEMA/EADA
28.9.2021 19:48:11 CEST | Business Wire | Press release
SKEMA Business School and EADA Business School have signed an agreement to launch a new joint double-degree BBA programme "SKEMA X EADA Global BBA" in Barcelona, where EADA operates.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928006004/en/
Through this alliance, SKEMA intends to develop a new European base from EADA's Barcelona campus. EADA will benefit from the presence of SKEMA’s campuses in five continents. At the same time, the two schools also aim to open this new four-year post-baccalaureate programme to candidates from Spanish-speaking countries.
"This post-baccalaureate double-degree programme is a new opportunity to develop SKEMA’s brand in the European continent and South America with EADA. It also offers our students in the SKEMA Global BBA – a programme which has 50% international students representing more than 60 different nationalities – the possibility of studying on the EADA campus and immersing themselves in the global city of Barcelona, with its ultra-dynamic economic centre, where they will be able to follow the sustainable innovation specialisation," explains Patrice Houdayer, Director of Programmes, International and Student Life at SKEMA Business School.
"As part of its development, EADA wanted to enter the field of post-baccalaureate BBA programmes, by favouring a partnership with a school that is highly recognised internationally. This is possible thanks to SKEMA, which will design a programme with us that meets the best international BBA standards, and which will confer the degree of bachelor and the visa," says Jordi Diaz, Dean at EADA.
From September 2022, students in the new EADA X SKEMA Global BBA double-degree programme will be able to spend the first two years on the EADA campus in Barcelona, then go on a mobility programme in the third year on one of SKEMA's seven campuses across the world, and then spend their fourth year either in Barcelona or on one of SKEMA's campuses, depending on the specialisation they have chosen.
About SKEMA Business School
With 9,500 students of 120 nationalities and 50,000 graduates in 145 countries, SKEMA Business School is a global school which, through its research, its +70 teaching programmes, its international multi-site structure trains and educates the talents that 21st century businesses need. The school is now present on 7 locations across 5 countries: 3 campuses in France (Lille, Sophia Antipolis, Paris), 1 in China (Suzhou), 1 in the United States (Raleigh), 1 in Brazil (Belo Horizonte) and 1 in South Africa (Cape Town - Stellenbosch).
SKEMA’s Faculty composed of 180 professors is divided into 3 academies (Globalisation, Innovation, Digitalisation). The Research Department has 5 research centres representing the main dimensions of management. The school has also established its Artificial Intelligence research and resource centre in Montreal.
SKEMA Ventures, SKEMA's incubation-acceleration dedicated device, has incubated over 250 projects.
SKEMA is multiaccredited - Equis, AACSB and EFMD Accredited EMBA. Its programmes are recognized in France (Visa, ‘licence’ Degree, Master Degree, RNCP, CGE label), as well as in the United States (Licensing), Brazil (Certificação) and China (Ministry of Education).
www.skema.edu . Follow us on Twitter: @SKEMA_BS
About EADA Business School
EADA Business School Barcelona was founded in 1957 as a private and independent institution. It has EQUIS (EFMD) and AMBA accreditations and is ranked 28th best business school in Europe by the Financial Times, top 45 best schools in Executive Education and its MBA is ranked 21st in Europe and 78th worldwide. With a renovated 4,000m2 campus in the centre of Barcelona and its residential campus in Collbató being the largest in Europe (15 hectares), today its Alumni community is represented by more than 100,000 members of 65 different nationalities and, after 64 years of history, its mission continues to be to promote the professional development and growth of people, as well as the transformation of organisations, in order to contribute to a more just, supportive and sustainable life. The axes on which it supports its learning model are innovation, sustainability and leadership.
www.eada.edu/es . Follow it on LinkedIn : @EADABusinessSchool
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928006004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom